Postoperative sleep disorder and gastrointestinal function recovery
Conditions
Interventions
DEX 1 group:DEX 200 ug uesd for PCIA
DEX 2 group:DEX 400 ug used for PCIA
DEX 0 group:DEX 0 ug/kg/h uesd for PCIA
Sponsors
Affiliated Tumor Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
25 Years to 77 Years
Inclusion criteria
Inclusion criteria: 1. The patient agrees to participate voluntarily and sign the informed consent in person or by the legal guardian; 2. The American society of anesthesiologists (ASA) I - III level; 3. Aged >=18 years, gender not limited; 4. Patients undergoing extensive radical resection of colorectal cancer under general anesthesia and laparoscopic extensive radical resection of colorectal cancer; 5. Patients who agreed to receive continuous pumping of postoperative analgesia pump after surgery.
Exclusion criteria
Exclusion criteria: 1. Allergy to dexmedetomidine or any drug used in this study; 2. Patients with mental system diseases (such as schizophrenia, depression, etc.) or family history of mental illness and cognitive impairment;Patients with a history of epilepsy or Parkinson's disease;Patients with a past history of abuse of psychotropic, narcotic or non-steroidal anti-inflammatory drugs; 3. The filter is bradycardia (heart rate or less 50 times/min), a second II type and above atrioventricular block (not including the use of pacemaker patients), and other serious arrhythmia history; 4. A history of sleep disorders (hypnotics/tranquilizers needed last month) and obstructive sleep apnea hypopnea syndrome; 5. Alanine aminotransferase (ALT) and/or aspartic aminotransferase (AST) exceeded the normal upper limit by 1.5 times, or had a history of liver dysfunction; 6. Emergency operation and second operation within one week; 7. The intraoperative blood loss was greater than 800ml and hemodynamics could not be maintained. 8. The patient received general anesthesia within 7 days; 9. History of myocardial infarction and history of unstable cardiac distractibility within 6 months before the screening period; 10. Patients whose Sp02 value was less than 92% in the non-oxygen state during the screening period; 11. Patients with systolic blood pressure = 11.1mmol/l during the screening period for diabetic patients whose blood glucose was not satisfactorily controlled; 13. Abnormal renal function, serum creatinine (Cr) or UREA greater than the upper limit of normal value;Or dialysis patients;14. The abnormal coagulation function has clinical significance, has bleeding tendency (such as active gastrointestinal ulcer) or is receiving thrombolysis or anticoagulation treatment; 15. Patients who had received a2 agonist or a2 antagonist within 7 days before surgery; 16. Pregnant or lactating women; 17. Participated in clinical trials of other drugs within three months; 18. Other circumstances in which the investigator determined that the patient was not eligible to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| gastrointestinal function recovery;sleep disorder; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain scores by VAS; | — |
Countries
China
Contacts
Public ContactFei Han
Affiliated Tumor Hospital of Harbin Medical University
Outcome results
None listed